Primitive neuroectodermal tumor
MONDO:0005462A malignant neoplasm that originates in the neuroectoderm. The neuroectoderm constitutes the portion of the ectoderm of the early embryo that gives rise to the central and peripheral nervous systems and includes some glial cell precursors.
Also known as: PNET, neuroectodermal neoplasm, neuroectodermal tumor, neuroectodermal tumour, primitive neuroectodermal neoplasm, primitive neuroectodermal tumor, primitive neuroectodermal tumor (PNET), primitive neuroectodermal tumour (PNET)
1651 clinical trials for this condition and its sub-types, 14 tagged with Primitive neuroectodermal tumor itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Primitive neuroectodermal tumor
-
Neuroblastic tumor 3 trials · 206 incl. sub-types
3 sub-types
- Neuroblastoma 198 trials · 204 incl. sub-types Sub-types →
- Ganglioneuroblastoma 20 trials · 21 incl. sub-types Sub-types →
- Ganglioneuroma 5 trials Sub-types →
-
Central nervous system primitive neuroectodermal neoplasm 8 trials · 24 incl. sub-types
8 sub-types
- Intracranial primitive neuroectodermal tumor 0 trials · 8 incl. sub-types Sub-types →
- Childhood central nervous system primitive neuroectodermal neoplasm 6 trials Sub-types →
- Ependymoblastoma 5 trials Sub-types →
- Ganglioneuroma 5 trials Sub-types →
- Central nervous system tumor with bcor internal tandem duplication 1 trial
- Adult central nervous system primitive neuroectodermal neoplasm 0 trials Sub-types →
- Spinal cord neuroblastoma 0 trials
- Spinal cord primitive neuroectodermal tumor 0 trials
-
Peripheral primitive neuroectodermal tumor 8 trials · 9 incl. sub-types
3 sub-types
-
Melanotic neuroectodermal tumor 0 trials
Most studied deeper sub-types
-
Killer virus turned against childhood brain cancer
Disease control Recruiting nowThis early-stage trial tests whether a specially engineered herpes virus (G207) is safe to inject directly into the brain tumors of children whose cancer has returned. Up to 24 children aged 3 to 21 will receive the virus, and some will also get a small dose of radiation to help …
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New targeted drug shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called repotrectinib in people with advanced solid tumors that have certain gene changes (ALK, ROS1, or NTRK). The trial has two parts: first, finding a safe dose, and second, seeing how well the drug shrinks tumors. About 500 adults with advanced canc…
Phase 1/2 • Sponsor: Turning Point Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New hope for rare cancers: immunotherapy drug targets tumors regardless of origin
Disease control Recruiting nowThis study tests the drug nivolumab in people with advanced rare cancers that have a specific marker (PD-L1). The goal is to see if the drug can shrink or control the tumors when other treatments have stopped working. Up to 28 adults will receive treatment for up to 12 months, an…
Phase 2 • Sponsor: Instituto do Cancer do Estado de São Paulo • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Engineered immune cells take aim at childhood brain cancers
Disease control Recruiting nowThis early-phase study tests whether a new type of immunotherapy, called B7-H3 CAR T cells, can be safely given directly into the brain or spinal fluid of children and young adults with aggressive brain tumors like DIPG, DMG, or other recurrent central nervous system cancers. The…
Phase 1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New pill shows promise in early brain tumor trial
Disease control Recruiting nowThis early-stage study tests an oral drug called ONC206 in adults with brain tumors that have come back. The main goal is to find the safest dose and check for side effects. About 102 participants will take the drug once or several times a week.
Phase 1 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New stem cell combo aims to beat childhood cancers
Disease control Recruiting nowThis early-phase trial tests a new type of stem cell transplant for children with blood cancers or solid tumors that have relapsed or not responded to standard treatment. Doctors use a half-matched donor's stem cells, specially filtered to remove certain immune cells, and give th…
Phase 1 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New hope for VHL patients: belzutifan trial targets rare tumor disorder
Disease control Recruiting nowThis study tests the drug belzutifan in 100 people with von Hippel-Lindau (VHL) syndrome, a genetic condition that causes tumors in various organs. Researchers will track how well the drug shrinks tumors and how long it takes for the disease to progress, while also monitoring sid…
Phase 2 • Sponsor: José Claudio Casali da Rocha • Aim: Disease control
Last updated Jun 26, 2026 15:43 UTC